Please assess the completion status of the following clinical trial:

Trial Title: Study of Continuous Cardiac Monitoring to Assess Atrial Fibrillation After Cryptogenic Stroke

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Recent cryptogenic symptomatic transient ischemic attack (TIA) or cryptogenic ischemic stroke.~Exclusion Criteria:~1. Known etiology of TIA or stroke.~2. Untreated hyperthyroidism.~3. Myocardial infarction less than 1 month prior to stroke or TIA.~4. Coronary bypass grafting less than 1 month prior to stroke or TIA.~5. Valvular disease requiring immediate surgical intervention.~6. History of AF or atrial flutter.~7. Patent Foramen Ovale (PFO) and PFO is or was an indication to start oral anticoagulation (OAC).~8. Permanent indication for OAC at enrollment.~9. Permanent contra-indication for OAC.~10. Included in another clinical trial.~11. Life expectancy less than 1 year.~12. Pregnant.~13. Indicated for Implantable Pulse Generator (IPG), Implantable Cardioverter-Defibrillator (ICD), Cardiac Resynchronization Therapy (CRT) or an implantable hemodynamic monitoring system.~14. Not fit, unable or unwilling to follow the required procedures of the protocol.

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Continuous Monitoring (Type: ACTIVE_COMPARATOR): Continuous cardiac monitoring by the Reveal® XT Insertable Cardiac Monitor
- Control Arm (Type: NO_INTERVENTION): Follow-up at the same frequency, but with no Insertable Cardiac Monitor

Based on this trial design, predict the completion outcome and termination type (if applicable).